Report of Foreign Issuer (6-k)
June 05 2020 - 6:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June, 2020
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrants name into English)
4th Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Exhibit Index
|
|
|
Exhibit No.
|
|
Exhibit
|
|
|
10.1
|
|
Form of Securities Purchase Agreement, dated June 3, 2020, by and among Mereo BioPharma Group PLC and the several purchasers named therein
|
|
|
10.2
|
|
Form of Registration Rights Agreement, dated June 3, 2020, by and between Mereo BioPharma Group PLC and the several purchasers named therein
|
|
|
10.3
|
|
Form of Convertible Loan Note Instrument, dated June 3, 2020, relating to Mereo BioPharma Group PLC
|
|
|
10.4
|
|
Form of Warrant Instrument, dated June 3, 2020, relating to Mereo BioPharma Group PLC
|
|
|
99.1
|
|
Press release dated June 4, 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: June 4, 2020
|
|
|
MEREO BIOPHARMA GROUP PLC
|
|
|
By:
|
|
/s/ Denise Scots-Knight, Ph.D.
|
|
|
Name: Denise Scots-Knight, Ph.D.
|
|
|
Title: Chief Executive Officer
|
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Apr 2023 to Apr 2024